证券代码：688105 证券简称：诺唯赞 公告编号：2025-041 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/20 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 6 6 月 18 | 年 | 月 | 19 | 日~2026 | 年 | 日 | | 预计回购金额 | 500万元~1,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 4万股 | | | | | | | | 累计已回购股数占总股本比例 | 0.01% | | | | | | | | 累计已回购金额 | 97.38万元 | | | | | | | | 实际回购价格区间 | 24.26元/股~24.3 ...

Core Insights - On September 30, 2023, NuoVivian's stock increased by 0.74% with a trading volume of 63.6461 million yuan [1] - The company reported a financing buy-in of 7.3556 million yuan and a financing repayment of 7.1542 million yuan, resulting in a net financing buy of 201,500 yuan [1] - As of September 30, the total margin balance for NuoVivian was 96.7 million yuan, indicating a high level of financing activity [1] Financing Summary - On the same day, NuoVivian's financing buy-in was 7.3556 million yuan, with a current financing balance of 95.9805 million yuan, accounting for 1.04% of the circulating market value [1] - The financing balance is above the 80th percentile level over the past year, indicating a high position [1] Securities Lending Summary - NuoVivian repaid 1,666 shares in securities lending and sold 200 shares, with a selling amount of 4,642 yuan based on the closing price [1] - The remaining securities lending volume was 31,000 shares, with a balance of 719,500 yuan, also exceeding the 90th percentile level over the past year [1] Company Overview - NuoVivian Biotechnology Co., Ltd. was established on March 16, 2012, and went public on November 15, 2021 [2] - The company focuses on the research and development of functional proteins and high molecular organic materials, with a revenue composition of 81.86% from biological reagents, 9.99% from diagnostic reagents, and smaller percentages from other categories [2] - As of June 30, 2023, the number of shareholders increased by 2.37% to 8,596, while the average circulating shares per person decreased by 2.31% to 46,269 shares [2] Financial Performance - For the first half of 2023, NuoVivian reported a revenue of 606 million yuan, a year-on-year decrease of 6.63%, and a net profit attributable to shareholders of 3.1294 million yuan, down 80.63% year-on-year [2] Dividend Information - Since its A-share listing, NuoVivian has distributed a total of 731 million yuan in dividends, with 611 million yuan distributed over the past three years [3]

Group 1 - The core viewpoint of the news is that NuoVas has shown fluctuations in its stock price and financial performance, with a recent increase in stock price but a decline in revenue and net profit year-on-year [1][2]. - As of September 26, NuoVas' stock price increased by 2.03% to 23.13 CNY per share, with a total market capitalization of 9.2 billion CNY [1]. - The company has experienced a net outflow of main funds amounting to 1.6385 million CNY, with significant selling activity observed [1]. Group 2 - NuoVas operates in the pharmaceutical and biotechnology sector, specifically in the sub-sector of biological products, and is involved in gene sequencing, antigen testing, and in vitro diagnostics [2]. - For the first half of 2025, NuoVas reported a revenue of 606 million CNY, representing a year-on-year decrease of 6.63%, and a net profit of 3.1294 million CNY, down 80.63% compared to the previous year [2]. - The company has distributed a total of 731 million CNY in dividends since its A-share listing, with 611 million CNY distributed over the past three years [3].

Core Insights - NuoVance Biotechnology Co., Ltd. has experienced a decline in revenue and net profit for the first half of 2025, with a revenue of 606 million yuan, down 6.63% year-on-year, and a net profit of 3.13 million yuan, down 80.63% year-on-year [2] Group 1: Company Overview - NuoVance was established on March 16, 2012, and went public on November 15, 2021 [2] - The company focuses on the research and development of functional proteins and high molecular organic materials, with its main business segments including biological reagents (81.86%), diagnostic reagents (9.99%), consumables (3.15%), equipment (2.96%), technical services (1.85%), and others (0.18%) [2] - As of June 30, the number of shareholders increased by 2.37% to 8,596, while the average circulating shares per person decreased by 2.31% to 46,269 shares [2] Group 2: Financial Performance - For the first half of 2025, NuoVance reported a revenue of 606 million yuan, a decrease of 6.63% compared to the previous year, and a net profit of 3.13 million yuan, which is a significant drop of 80.63% year-on-year [2] - The company has distributed a total of 731 million yuan in dividends since its A-share listing, with 611 million yuan distributed over the past three years [3] Group 3: Market Activity - On September 25, NuoVance's stock price increased by 0.09%, with a trading volume of 66.34 million yuan [1] - The financing buy-in amount for NuoVance on the same day was 4.45 million yuan, while the financing repayment was 5.28 million yuan, resulting in a net financing outflow of 835,200 yuan [1] - The total balance of margin trading for NuoVance reached 101 million yuan, with the financing balance accounting for 1.11% of the circulating market value, indicating a high level compared to the past year [1]

Policy Developments - The National Healthcare Security Administration (NHSA) has announced a public solicitation for information on innovative medical consumables, including brain-machine interface technologies and surgical robots, to streamline the coding process for these products [2] Drug and Device Approvals - Fosun Pharma's subsidiary, Fosun Kary, has had its drug registration application for Brexucabtagene Autoleucel accepted by the National Medical Products Administration, aimed at treating relapsed or refractory B-cell acute lymphoblastic leukemia in adults [4] - Novogene's subsidiary has received medical device registration certificates for several neurodiagnostic reagents, which can assist in diagnosing Alzheimer's and Parkinson's diseases [5] Capital Market Activities - Hengrui Medicine has signed a licensing agreement for its innovative drug SHR-A1811, receiving an upfront payment of $18 million and potential milestone payments up to $1.093 billion, which will enhance its overseas market presence [7] - Yong'an Pharmaceutical plans to acquire a 49.20% stake in its subsidiary Ling'an Technology for 27 million yuan, aiming to strengthen control and reduce management costs [8] Industry Events - The NHSA hosted discussions with domestic and international investment institutions, emphasizing support for the high-quality development of innovative drugs and the implementation of policies to facilitate this growth [10] - Illumina has announced partnerships with several global pharmaceutical companies to develop companion diagnostics based on its TruSight Oncology genomic testing platform, focusing on KRAS gene mutations [11] Regulatory and Governance Updates - The former deputy director of the Henan Provincial Medical Security Bureau is under investigation for serious violations of discipline and law [13] - Shareholder Wang Xiaopeng of Huyou Pharmaceutical plans to reduce his stake by up to 3% due to personal financial needs [14] - Independent director Huang Zhengming of Qidi Pharmaceutical has resigned due to work reasons, which may affect the board's composition [15]

Group 1 - The company, Nanjing Novogene Biotechnology Co., Ltd., has announced that its subsidiary has obtained medical device registration certificates for multiple diagnostic reagent products related to neurological diseases [1][4] - Alzheimer's Disease (AD) is highlighted as a significant public health issue due to the aging global population, leading to memory impairment and cognitive decline [1][2] - The company has developed several blood biomarkers for AD, making it the largest manufacturer in China for AD core biomarker detection through blood samples [2][3] Group 2 - Parkinson's Disease (PD) is identified as the second most common neurodegenerative disease, characterized by the loss of dopaminergic neurons and the aggregation of α-synuclein [3] - The oligomerization rate of α-synuclein is noted as an effective predictor for distinguishing PD patients from healthy controls, and it serves as a specific marker for differentiating between AD and other α-synucleinopathies [3] - The company aims to enhance its product offerings in the central nervous system disease area, focusing on innovative detection and diagnostic products for PD and brain injuries [2][3]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Nanjing Novogene Medical Technology Co., Ltd., has obtained the Medical Device Registration Certificate in China for multiple diagnostic reagent products related to the nervous system [2] Group 1 - The announcement was made on the evening of September 24 [2] - The registered products are part of a series focused on the nervous system [2] - The achievement signifies a regulatory milestone for the company's product development in the medical device sector [2]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-040 南京诺唯赞生物科技股份有限公司 关于自愿披露子公司产品取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司（以下简称"公司"）全资子公司南京诺 唯赞医疗科技有限公司开发的多个神经系统系列诊断试剂产品，于近日取得我国 《医疗器械注册证》，具体情况如下： 一、产品注册相关情况 （一）医疗器械注册证基本信息 | 序 | 注册 | 注册证 | 名称 | 注册证编号 | 预期用途 | 号 | 分类 | 有效期至 | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非磷酸化 | Tau | 217 | 蛋 | 临 ...

Core Viewpoint - The company, Novogene (688105.SH), has announced that its wholly-owned subsidiary, Nanjing Novogene Medical Technology Co., Ltd., has obtained multiple medical device registration certificates for its series of diagnostic reagents for the nervous system in China [1] Group 1: Product Development and Innovation - The company is leveraging its proprietary antibody technology platform to continuously enrich its Alzheimer's disease blood test product series based on global authoritative guidelines [1] - The company is focusing on the central nervous system's major diseases by innovatively developing precise detection and diagnostic products for conditions such as Parkinson's disease and brain injuries [1] Group 2: Market Position and Strategy - The newly obtained product registration certificates signify that the company's related products have received market access qualifications in China [1] - The company aims to address unmet clinical needs in the field of neurological diseases, enhancing the product strength and influence of its chemiluminescence platform [1] - The company is committed to improving the diagnosis and treatment services for brain health and cognitive disorders in alignment with the "Healthy China Strategy" [1]

Core Viewpoint - The company, NuoVance (688105.SH), has announced that its wholly-owned subsidiary, Nanjing NuoVance Medical Technology Co., Ltd., has obtained multiple medical device registration certificates for its series of diagnostic reagents for neurological systems, indicating market entry approval in China [1] Group 1: Product Development and Innovation - The company is leveraging its proprietary antibody technology platform to continuously enrich its Alzheimer's disease blood test series products based on global authoritative guidelines [1] - The focus is on developing innovative products for precise detection and diagnosis of major central nervous system diseases, including Parkinson's disease and brain injuries, addressing unmet clinical needs in the field of neurological diseases [1] Group 2: Strategic Goals and Market Impact - The company aims to enhance the product strength and influence of its chemiluminescence platform, contributing to the improvement of brain health and cognitive disorder diagnosis and treatment services in China [1] - The acquisition of these product registration certificates represents a significant step in actively implementing the "Healthy China Strategy" [1]